More than one-third of patients do not tell their physicians all of the prescription and over-the-counter medications that they are taking.
More than one-third of patients do not tell their physicians all of the prescription and over-the-counter medications that they are taking, according to a recent survey sponsored by Milwaukee-based Schwarz Pharma.
In a survey of 1,000 adults, 38% reported that they did not always give their physicians a complete list of all medications taken. And although more women (70%) than men (53%) informed their doctor of their medications, and the quality of patient-physician communication improved with the patient's age, 58% of all adults who reported taking prescription medication reported minor side effects, such as dizziness, nausea or shortness of breath.
"Some incidence of side effects with any prescription or even over-the-counter medication is inherent," said Klaus Veitinger, president of Schwarz Pharma. "The more important issueâ¦is the potential for adverse interaction resulting in side effects when patients are taking multiple prescription and/or over-the-counter medicines."
The importance of fully disclosing medication regimens increases with a patient's age, as many patients find themselves taking multiple prescription products to combat a variety of age-related afflictions.
Based on its survey results, Schwarz Pharma recommended the following:
• Patients should carry a list of the medications they are taking, both prescription and over-the-counter.
• Patients should make certain the list is included with their medical records and is updated to reflect changes.
• Patients need to ask their physicians and pharmacists about possible side effects and adverse reactions when they are prescribed a new medication.
Schwarz Pharma also recommended that patients, physicians and pharmacists carefully read product literature. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.